CN117794932A - 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物 - Google Patents

可用作wee1激酶抑制剂的吡啶并嘧啶衍生物 Download PDF

Info

Publication number
CN117794932A
CN117794932A CN202280054331.6A CN202280054331A CN117794932A CN 117794932 A CN117794932 A CN 117794932A CN 202280054331 A CN202280054331 A CN 202280054331A CN 117794932 A CN117794932 A CN 117794932A
Authority
CN
China
Prior art keywords
cancer
compound
tumor
carcinoma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280054331.6A
Other languages
English (en)
Chinese (zh)
Inventor
O·吉拉德
J·瓦卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apuli Treatment Co ltd
Original Assignee
Apuli Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apuli Treatment Co ltd filed Critical Apuli Treatment Co ltd
Publication of CN117794932A publication Critical patent/CN117794932A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280054331.6A 2021-06-04 2022-06-03 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物 Pending CN117794932A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196744P 2021-06-04 2021-06-04
US63/196,744 2021-06-04
PCT/US2022/032203 WO2022256680A1 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Publications (1)

Publication Number Publication Date
CN117794932A true CN117794932A (zh) 2024-03-29

Family

ID=82321319

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280054331.6A Pending CN117794932A (zh) 2021-06-04 2022-06-03 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物

Country Status (10)

Country Link
US (1) US20240254123A1 (enExample)
EP (1) EP4347592A1 (enExample)
JP (1) JP2024522304A (enExample)
KR (1) KR102997319B1 (enExample)
CN (1) CN117794932A (enExample)
AU (2) AU2022287033B2 (enExample)
CA (1) CA3225152A1 (enExample)
IL (1) IL309037A (enExample)
MX (1) MX2023014466A (enExample)
WO (1) WO2022256680A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240158972A (ko) 2022-03-07 2024-11-05 데비오팜 인터네셔날 에스 에이 소세포 폐암의 치료 방법
EP4777102A1 (en) 2023-09-14 2026-07-22 Debiopharm International SA Combination of a wee1 inhibitor and a pkmyt1 inhibitor
CN120189510A (zh) * 2023-12-21 2025-06-24 北京哲源科技有限责任公司 一种并环化合物的应用
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2022287033B2 (en) 2025-04-17
AU2022287033A1 (en) 2024-01-18
WO2022256680A1 (en) 2022-12-08
MX2023014466A (es) 2024-05-02
KR102997319B1 (ko) 2026-07-30
EP4347592A1 (en) 2024-04-10
US20240254123A1 (en) 2024-08-01
AU2025204724A1 (en) 2025-07-10
CA3225152A1 (en) 2022-12-08
KR20240044409A (ko) 2024-04-04
JP2024522304A (ja) 2024-06-13
IL309037A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US20240316004A1 (en) Methods of treating mutant lymphomas
AU2018358160B2 (en) Modulators of the integrated stress pathway
AU2022287033B2 (en) Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
JP7014731B2 (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
US9861643B2 (en) System and method for diagnosis and treatment
ES2895419T3 (es) Formas sólidas de (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexan-1-carboxamida y métodos para su uso
TW201242601A (en) Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
MX2015003114A (es) Metodos para el tratamiento de cancer de mama localmente avanzado.
WO2022051569A1 (en) Substituted 3-piperidinyl-pyrrolo[2,3-b]pyridines and related compounds and their use in treating medical conditions
US20250199015A1 (en) Cyclin-dependent kinase 2 inhibitors for medical treatment
EP2575818A2 (en) The use of inhibitors of bruton's tyrosine kinase (btk)
WO2022051567A1 (en) Substituted pyrido[2,3-b]pyrazinones and reuated compounds and their use in treating medicau conditions
CN119013266A (zh) 新颖gspt1化合物以及新颖化合物的使用方法
WO2023009833A9 (en) Multi-cyclic irak and flt3 inhibiting compounds and uses thereof
HK40107981A (en) Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
HK1226057B (en) Substituted pyrimidine bmi-1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107981

Country of ref document: HK